BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in Lexeo Therapeutics, Inc. common stock. BlackRock reports beneficial ownership of 4,885,814 shares, representing 6.7% of Lexeo's outstanding common stock as of the event date 12/31/2025.
The filing states that BlackRock has sole power to vote 4,838,218 shares and sole power to dispose of 4,885,814 shares, with no shared voting or dispositive power. The shares are held by certain BlackRock business units in the ordinary course of business and are not held for the purpose of changing or influencing control of Lexeo. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Lexeo’s outstanding common shares.
Positive
None.
Negative
None.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Lexeo Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
52886X107
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
52886X107
1
Names of Reporting Persons
BlackRock, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
4,838,218.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
4,885,814.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,885,814.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.7 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Lexeo Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
345 PARK AVENUE SOUTH, FLOOR 6 NEW YORK NY 10010
Item 2.
(a)
Name of person filing:
BlackRock, Inc.
In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)
Address or principal business office or, if none, residence:
BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)
Citizenship:
See Item 4 of Cover Page
(d)
Title of class of securities:
Common Stock
(e)
CUSIP No.:
52886X107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
4885814
(b)
Percent of class:
6.7 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
4838218
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
4885814
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Lexeo Therapeutics, Inc.. No one person's interest in the common stock of Lexeo Therapeutics, Inc. is more than five percent of the total outstanding common shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See Exhibit 99
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What does the BlackRock Schedule 13G filing reveal about Lexeo Therapeutics (LXEO)?
The Schedule 13G shows that BlackRock, Inc. holds a passive stake in Lexeo Therapeutics, Inc., beneficially owning 4,885,814 shares of common stock, equal to 6.7% of the outstanding class as of 12/31/2025.
How many Lexeo Therapeutics (LXEO) shares does BlackRock beneficially own and what percentage is this?
BlackRock reports beneficial ownership of 4,885,814 Lexeo common shares, representing 6.7% of the company’s outstanding common stock as referenced in the filing.
What voting and dispositive power does BlackRock report over Lexeo Therapeutics (LXEO) shares?
BlackRock reports sole voting power over 4,838,218 Lexeo shares and sole dispositive power over 4,885,814 shares, with 0 shared voting or shared dispositive power.
Is BlackRock’s stake in Lexeo Therapeutics (LXEO) intended to influence control of the company?
No. The certification states the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of changing or influencing the control of Lexeo Therapeutics.
Who ultimately benefits from BlackRock’s Lexeo Therapeutics (LXEO) holdings?
The filing notes that various persons have the right to receive dividends or sale proceeds from the Lexeo common stock held by BlackRock’s business units, and that no one person’s interest exceeds five percent of Lexeo’s total outstanding common shares.
What type of reporting person is BlackRock in this Lexeo Therapeutics (LXEO) Schedule 13G?
BlackRock is classified in the filing as type HC, indicating it is a parent holding company or control person under the Schedule 13G reporting categories.
Who signed the BlackRock Schedule 13G related to Lexeo Therapeutics (LXEO)?
The Schedule 13G is signed by Spencer Fleming, identified as a Managing Director, certifying that the information in the statement is true, complete, and correct.
